Beger HG, Rau B, Isenmann R Natural history of necrotizing pancreatitis. Pancreatology. 2003;3(2):93-101. doi: 10.1159/000070076. No abstract available.
Beger HG, Rau BM Severe acute pancreatitis: Clinical course and management. World J Gastroenterol. 2007 Oct 14;13(38):5043-51. doi: 10.3748/wjg.v13.i38.5043.
Lachance P, Chen J, Featherstone R, Sligl WI Association Between Cytomegalovirus Reactivation and Clinical Outcomes in Immunocompetent Critically Ill Patients: A Systematic Review and Meta-Analysis. Open Forum Infect Dis. 2017 Feb 13;4(2):ofx029. doi: 10.1093/ofid/ofx029. eCollection 2017 Spring.
Li X, Huang Y, Xu Z, Zhang R, Liu X, Li Y, Mao P Cytomegalovirus infection and outcome in immunocompetent patients in the intensive care unit: a systematic review and meta-analysis. BMC Infect Dis. 2018 Jun 28;18(1):289. doi: 10.1186/s12879-018-3195-5.
Petrov MS, Shanbhag S, Chakraborty M, Phillips AR, Windsor JA Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. Gastroenterology. 2010 Sep;139(3):813-20. doi: 10.1053/j.gastro.2010.06.010. Epub 2010 Jun 9.
Schmidt PN, Roug S, Hansen EF, Knudsen JD, Novovic S Spectrum of microorganisms in infected walled-off pancreatic necrosis - impact on organ failure and mortality. Pancreatology. 2014 Nov-Dec;14(6):444-9. doi: 10.1016/j.pan.2014.09.001. Epub 2014 Sep 16.
Thoeni RF The revised Atlanta classification of acute pancreatitis: its importance for the radiologist and its effect on treatment. Radiology. 2012 Mar;262(3):751-64. doi: 10.1148/radiol.11110947.
Trikudanathan G, Navaneethan U, Vege SS Intra-abdominal fungal infections complicating acute pancreatitis: a review. Am J Gastroenterol. 2011 Jul;106(7):1188-92. doi: 10.1038/ajg.2010.497.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.